A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Latest Information Update: 12 Jul 2024
At a glance
- Drugs Apalutamide (Primary) ; Abiraterone acetate; Docetaxel; Prednisolone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 27 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Oct 2025.
- 22 Aug 2022 Planned End Date changed from 1 Jun 2021 to 1 Jun 2023.
- 22 Mar 2021 Status changed from recruiting to active, no longer recruiting.